Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew C Riddle

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
Diabetes Care|October 28, 2003
The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patientsMatthew C Riddle, Julio Rosenstock, John Gerich, et al.
Diabetes, Obesity & Metabolism|September 13, 2017
Insulin resistance and cardiovascular outcomes in the ORIGIN trialHertzel C Gerstein, Ele Ferrannini, Matthew C Riddle, et al.
Clinical Endocrinology|October 7, 2011
Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin secretion and actionKevin C J Yuen, Patricia A McDaniel, Matthew C Riddle
Diabetes Care|September 22, 2017
Diabetes Research and Care Through the AgesBernard Zinman, Jay S Skyler, Matthew C Riddle, et al.
Diabetes Care|February 11, 2012
Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trialAmbady Ramachandran, Matthew C Riddle, Conrad Kabali, et al.
Diabetes Care|January 22, 2020
Red and Processed Meats and Health Risks: How Strong Is the Evidence?Frank Qian, Matthew C Riddle, Judith Wylie-Rosett, et al.
American Heart Journal|December 18, 2007
Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention), Hertzel Gerstein, Salim Yusuf, et al.
Clinical Therapeutics|October 9, 2007
Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitusPeter Mullins, Peter Sharplin, Hannele Yki-Jarvinen, et al.
Journal of the American Geriatrics Society|April 16, 2013
Contributions of basal and prandial hyperglycemia to total hyperglycemia in older and younger adults with type 2 diabetes mellitusMedha N Munshi, Naushira Pandya, Guillermo E Umpierrez, et al.
Diabetes Care|August 1, 2014
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)Matthew C Riddle, Geremia B Bolli, Monika Ziemen, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Diabetes Care|October 28, 2003
The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patientsMatthew C Riddle, Julio Rosenstock, John Gerich, et al.
Diabetes, Obesity & Metabolism|September 13, 2017
Insulin resistance and cardiovascular outcomes in the ORIGIN trialHertzel C Gerstein, Ele Ferrannini, Matthew C Riddle, et al.
Clinical Endocrinology|October 7, 2011
Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin secretion and actionKevin C J Yuen, Patricia A McDaniel, Matthew C Riddle
Diabetes Care|September 22, 2017
Diabetes Research and Care Through the AgesBernard Zinman, Jay S Skyler, Matthew C Riddle, et al.
Diabetes Care|February 11, 2012
Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trialAmbady Ramachandran, Matthew C Riddle, Conrad Kabali, et al.
Diabetes Care|January 22, 2020
Red and Processed Meats and Health Risks: How Strong Is the Evidence?Frank Qian, Matthew C Riddle, Judith Wylie-Rosett, et al.
American Heart Journal|December 18, 2007
Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention), Hertzel Gerstein, Salim Yusuf, et al.
Clinical Therapeutics|October 9, 2007
Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitusPeter Mullins, Peter Sharplin, Hannele Yki-Jarvinen, et al.
Journal of the American Geriatrics Society|April 16, 2013
Contributions of basal and prandial hyperglycemia to total hyperglycemia in older and younger adults with type 2 diabetes mellitusMedha N Munshi, Naushira Pandya, Guillermo E Umpierrez, et al.
Diabetes Care|August 1, 2014
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)Matthew C Riddle, Geremia B Bolli, Monika Ziemen, et al.
Pageof 9